Skip to content
IconOVir
  • Contact
  • Contact

Day: July 11, 2023

IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042

— ICVB-1042 is an oncolytic adenovirus for the treatment of advanced solid tumors —— Initial safety data expected in 2H 2023, followed by proof-of-concept data in 2024 —  SAN DIEGO, CA., July 11, 2023 – IconOVir Bio, Inc. (IconOVir), a clinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the […]

CORPORATE OFFICE

IconOVir Bio
689 Fifth Ave, 12th Floor
New York, NY 10022

info@iconovir.com
Linkedin-in
©2025 IconOVir Bio